Breaking Finance News

A report released today by RBC Capital Markets about Insys Therapeutics (NASDAQ:INSY) bumps down the target price to $26.00

Having a price of $13.27, Insys Therapeutics (NASDAQ:INSY) traded -2.48% lower on the day. With the last stock price down -17.69% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. INSY has recorded a 50-day average of $15.48 and a two hundred day average of $15.26. Trade Volume was up over the average, with 1,056,601 shares of INSY changing hands over the typical 834,538

RBC Capital Markets dropped the price target of Insys Therapeutics (NASDAQ:INSY) to $26.00 reporting a possible upside of 0.96%.

Recent Performance Chart

Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics has PE ratio of 18.92 with a one year low of $11.45 and a one year high of $33.88 and has a market capitalization of $0.

A total of 5 brokerages have issued a ratings update on Insys Therapeutics. One brokerage rating the company a strong buy, three brokerages rating the company a buy, one brokerage rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $24.40.

General Company Details For Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *